Page 77 - The Vasculitides, Volume 1: General Considerations and Systemic Vasculitis

Overview of Primary and Secondary Vasculitides 53

autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and
prognosis. Arthritis Rheum. 2012; 64:3452-3462.
[60] Savage, C. O., Gaskin, G., Pusey, C. D., et al. Myeloperoxidase binds to vascular
endothelial cells, is recognized by ANCA and can enhance complement dependent
cytotoxicity. Adv. Exp. Med. Biol. 1993; 336:121-123.
[61] Jennette, J. C., Falk, R. J. Pathogenesis of ANCA-associated vasculitis: observations,
theories, and speculations. Presse Med. 2013; 42:493-498.
[62] Free, M. E., Ciavatta, D. J., Falk, R. J. How antigens influence the disease: An
immunologist point of view. Presse Med. 2013; 42:577-579.
[63] Jones, R. B., Ferraro, A. J., Chaudhry, A. N., et al. A multicenter survey of rituximab
for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis
Rheum. 2009; 60:2156-2168.
[64] Cartin-Ceba, R., Golbin, J. M., Keogh, K. A., et al. Rituximab for remission induction
and maintenance in refractory granulomatosis with polyangiitis (Wegener?s): ten-year
experience at a single center. Arthritis Rheum. 2012; 64:3770-3778.
[65] Holle, J. U., Dubrau, C., Herlyn, K., et al. Rituximab for refractory granulomatosis with
polyangiitis (Wegener?s granulomatosis): comparison of efficacy in granulomatous
versus vasculitic manifestations. Ann. Rheum. Dis. 2012; 71:327-333.
[66] Smith, R. M., Jones, R. B., Guerry, M. J., et al. Rituximab for remission maintenance in
relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum.
2012; 64:3760-3769.
[67] Roubaud-Baudron, C., Pagnoux, C., et al. Rituximab maintenance for granulomatosis
with polyangiitis and microscopic polyangiitis. J. Rheumatol. 2012; 39:125-130.
[68] Smith, R., Alberici, F., Jones, R., et al. Long term follow up of patients who received
repeat dose rituximab as maintenance therapy for ANCA associated vasculitis (AAV)
[Abstract]. Presse Med. 2013; 42:775-776.
[69] Stone, J. R., Merkel, P. A., Spiera, R., et al. Rituximab versus cyclophosphamide for
ANCA-associated vasculitis. N. Engl. J. Med. 2010; 363:221-232.
[70] Jayne, D., Smith, R., Merkel, P. An international, open label, randomised controlled
trial comparing rituximab with azathioprine as maintenance therapy in relapsing
ANCA-associated vasculitis (RITAZAREM) [Abstract]. Presse Med. 2013; 42:768.
[71] Miloslavsky, E., Specks, U., Merkel, P., et al. Retreatment with rituximab in the RAVE
trial [Abstract]. Presse Med. 2013; 42:778.
[72] Miloslavsky, E. M., Specks, U., Merkel, P., et al. Clinical outcomes of remission
induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
Arthritis Rheum. 2013; 65:2441-2449.
[73] Zeek, P. M., Smith, C. C., Weeter, J. C. Studies on periarteritis nodosa. III. The
differentiation between the vascular lesions of periarteritis nodosa and of
hypersensitivity. Am. J. Pathol. 1948; 24:889-917.
[74] Zeek, P. M. Periarteritis nodosa-a critical review. Am. J. Clin. Pathol. 1952; 22:777-
790.
[75] Zeek, P. M. Periarteritis nodosa and other forms of necrotizing angiitis. N. Engl. J.
Med. 1953; 248:764-772.
[76] Arthus, M., Breton, M. Lesions cutanées produites par les injections de sérum de cheval
chez le lapin anaphylactisé par et pour ce sérum. Compt. Rend. Soc. de Biol. 1903; 55:
1478-1480.

Complimentary Contributor Copy